Multiple Myeloma Clinical Trials

168 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

   Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. Participants will be randomized to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone. Treatment will co…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   Gundersen Lutheran, La Crosse, Wisconsin

   Run by

   PrECOG, LLC.

   See if you can join NCT07285239 on ClinicalTrials.gov

2. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

   The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06296368 on ClinicalTrials.gov

3. Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

   The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs fr…

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Joshua Sasine, MD, PhD

   See if you can join NCT05887167 on ClinicalTrials.gov

4. Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

   This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed prior therapies.

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT05976555 on ClinicalTrials.gov

5. Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

   Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06105554 on ClinicalTrials.gov

6. Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

   To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06207799 on ClinicalTrials.gov

7. Delayed Toxicities Post-CAR-T

   This is an observational umbrella protocol evaluating toxicities after CAR-T therapy with ciltacabtagene autoleucel (cilta-cel) for RRMM, with a goal to identify key inflammatory features contributing to toxicities, define non-invasive biomarkers to guide clinical monitoring, and evaluate treatment…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCSF Medical Center, San Francisco, California

   Locations

   3 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07665307 on ClinicalTrials.gov

8. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

   The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

   Stage

   Phase 1

   Ages

   12 to 80

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05092451 on ClinicalTrials.gov

9. Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

   This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a pers…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06483100 on ClinicalTrials.gov

10. Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

    Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell en…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Unversity of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT05135351 on ClinicalTrials.gov

11. Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

    This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transpla…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT07101445 on ClinicalTrials.gov

12. Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

    Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06461988 on ClinicalTrials.gov

13. Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

    The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    3 in total

    Run by

    Irene Ghobrial, MD

    See if you can join NCT05469893 on ClinicalTrials.gov

14. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    19 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06121843 on ClinicalTrials.gov

15. Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    25 in total

    Run by

    Karyopharm Therapeutics Inc

    See if you can join NCT02343042 on ClinicalTrials.gov

16. Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

    The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06340646 on ClinicalTrials.gov

17. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona

    Locations

    46 in total

    Run by

    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

18. CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

    The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

    Stage

    Not phased

    Ages

    30 and older

    Site

    Atrium Health Levine Cancer, Charlotte, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT06644625 on ClinicalTrials.gov

19. Pre-malignant States to Hematologic Malignancies in Firefighters

    The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

    Stage

    Not phased

    Ages

    40 to 49

    Site

    Levine Cancer Institute, Charlotte, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT06870760 on ClinicalTrials.gov

20. Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

    Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cel…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06185751 on ClinicalTrials.gov

21. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Scripps Clinic Torrey Pines, La Jolla, California

    Locations

    42 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05137054 on ClinicalTrials.gov

22. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whethe…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    11 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06083922 on ClinicalTrials.gov

23. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

    This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    UCI Health - Irvine Infusion Pharmacy ACC, Irvine, California

    Locations

    33 in total

    Run by

    Pfizer

    See if you can join NCT06057402 on ClinicalTrials.gov

24. Halt Aging in Survivors of Blood Cancers

    Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting th…

    Stage

    Not phased

    Ages

    50 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07292272 on ClinicalTrials.gov

25. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage

    Not phased

    Ages

    19 to 110

    Site

    Advent Health, Greenwood Village, Colorado

    Locations

    42 in total

    Run by

    University of Nebraska

    See if you can join NCT02012699 on ClinicalTrials.gov